StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report released on Tuesday. The firm issued a sell rating on the stock.
Oragenics Stock Performance
NYSE OGEN traded up $0.32 on Tuesday, hitting $1.40. The stock had a trading volume of 1,739,745 shares, compared to its average volume of 185,378. The firm’s 50-day simple moving average is $1.25. Oragenics has a one year low of $0.86 and a one year high of $7.74. The stock has a market cap of $6.27 million, a PE ratio of -0.16 and a beta of 0.50.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- What Are Dividend Challengers?
- MarketBeat Week in Review – 8/5 – 8/9
- What is Put Option Volume?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What is Short Interest? How to Use It
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.